The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

Moderna rises as CDC expands RSV vaccine guidance to include high-risk adults aged 50-59, boosting mResvia's reach.

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

Chronic heart failure and hypoalbuminaemia are linked to a poor antibody response at 3 months after the third dose of the ...

Arcturus has made progress in cost-cutting and focusing on CF and OTC deficiency. Click here to find out the factors that ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

The inaccurate rumours refer to a study looking at excess deaths during the pandemic in the German city of Frankfurt am Main.

If we don’t invest in technologies like mRNA vaccines for pandemic influenza now, once a virus starts going human-to-human, ...

Records show that a top U.S. regulator rejected the recommendations of agency experts and limited the use of Covid vaccines.

The world's first mRNA vaccine against Elephant Endotheliotropic Herpesvirus (EEHV) has reportedly shown promising results, ...

The revamped and “more anti-vax skewed ACIP committee” at the CDC “has a bone to pick with mRNA vaccines,” according to ...

The US Food and Drug Administration’s top vaccine official overrode agency experts in May to recommend against the broad use ...